Abstract 4215: SPAG5 upregulation predicts poor prognosis of cervical cancer patients and alters the sensitivity of Taxol treatment via mTOR signaling pathway

Abstract

Abstract Our previous work found SPAG5 to be upregulated in pelvic lymphnode metastasis positive cervical cancer, the aim of the present study was to examine the role of SPAG5 in proliferation and tumorigenicity of cervical cancers, and its clinical significance in tumor progression. By detecting SPAG5 expression in cervical cancer patients and exploring cervical cancer cell function with SPAG5 downregulation in vitro, our results revealed that SPAG5 upregulated in tumor tissue compared with paired adjacent noncancerous tissues, and the upregulation of SPAG5 in tumor tissues also indicated poor disease free survival which was also an independent prognostic indicator of cervical cancer patients. In vitro study demonstrated that SPAG5 downregulation inhibited cell proliferation and growth significantly by G2/M arrest and apoptosis induction, and also hindered cell migration and invasion. Further study showed different sensitivity of cervical cells to different doses of Taxol treatment under SPAG5 downregulation, which is correlated with mTOR signaling pathway activity. In this study, we demonstrated that SPAG5 upregulation related to poor prognosis of cervical cancer patients, and SPAG5 was a regulator of mTOR activity during Taxol treatment in cervical cancer. Note: This abstract was not presented at the meeting. Citation Format: Lin-Jing Yuan, Lan Zhang, Yun Zhou, Min Zheng. SPAG5 upregulation predicts poor prognosis of cervical cancer patients and alters the sensitivity of Taxol treatment via mTOR signaling pathway. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4215. doi:10.1158/1538-7445.AM2014-4215